

Paper No. B

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 2001-01

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of

**Complete if Known**

Application Number	09/721,495
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Art Unit	1644/1646
Examiner Name	Not yet assigned
Attorney Docket Number	019934-000721US

RECEIVED  
JUL 25 2002  
FBI CENTER 180012900

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MOP	AI	GenBank Accession Number AA215577; August 13, 1997	
	AJ	GenBank Accession Number AF233281; May 22, 2000	
	AK	GenBank Accession Number AI131555; October 26, 1998	
	AL	GenBank Accession Number AI769466; June 28, 1999	
	AM	GenBank Accession Number AR003970; December 10, 1998	
	AN	GenBank Accession Number AW190975; November 22, 1999	
	AO	GenBank Accession Number E12852; June 24, 1998	
	AP	GenBank Accession Number H67224; October 27, 1995	
	AQ	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000	
	AR	DATABASE EMBL Accession No. Y30125; 14 October 1999	
	AS	DAIRAGHI, DANIEL J.; et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	
	AT	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-1 Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	
	AU	GOSLING, JENNIFA, et al; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK; The Journal of Immunology; 2000; pp. 2851-2856	
	AV	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6, 7, 8 and 9; pp. viii-xv and 213-263; IRL Press at Oxford University Press Inc., New York, New York	
	AW	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; Biochemical and Biophysical Research Communications; July 15, 1993; pp. 504-511; Volume 194, No. 1	
MOP	AX	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; FEBS Letters 1996; pp 325-329	

Examiner  
Signature

MICHAEL PHA


Date  
Considered

3-17-03 / 12/8/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
DE 7076648 v1



Paper NO. C

PTO/SB/08B (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of

**Complete if Known**

Application Number	09/721,495
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa, et. al.
Art Unit	1646
Examiner Name	Pak, Michael D.
Attorney Docket Number	019934-000721US

**RECEIVED**

MAY 05 2003

TECH CENTER 1600/2900

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MDP	(A)	BORK, PEER, et al; Go hunting in sequence databases but watch out for the traps; <i>Trends in Genetics</i> ; October 1998; pp. 425-427; Vol. 12, No. 10	
↑	(B)	BORK, PEER; Powers and Pitfalls in Sequence Analysis: The 70% Hurdle; <i>Genome Research</i> ; 2000; pp. 398-400; Vol. 10	
	(C)	BRENNER, Steven E.; Errors in genome annotation; <i>Trends in Genetics</i> ; April 1999; pp. 132-133; Vol. 15, No. 4	
	(D)	DOERKS, TOBIAS, et al.; Protein annotation: detective work for function prediction; <i>Trends in Genetics</i> ; June 1998; pp. 248-250; Vol. 14, No. 6	
	(E)	NGO, J. THOMAS, et al; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox; <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. LeGrand, Editors; 1994; pp. 491-495; Birkhauser, Boston	
	(F)	SKOLNICK, JEFFREY, et al; From gene to protein structure and function: novel applications of computational approaches in the genomic era; <i>Trends in Biotech</i> ; 2000; pp. 34-39; Vol. 18, No. 1	
↓	(G)	SMITH, TEMPLE F., et al; The challenges of genome sequence annotation or "The devil is in the details"; <i>Nature Biotechnology</i> ; November 1997; pp. 1222-1223; Vol. 15	
MDP	(H)	Wells, James A.; Additivity of Mutational Effects in Proteins; <i>Biochemistry</i> ; September 18, 1990; pp. 8509-8517; Vol. 29, No. 37	

Examiner Signature	MICHAEL PAK	Date Considered	12/18/03
-----------------------	-------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7101460 v1